1. Yarden, Y. & Shilo, B.Z. SnapShot: EGFR signaling pathway. Cell 131, 1018 (2007).
  2. Yarden, Y. & Pines, G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 12, 553-63 (2012).
  3. Citri, A. & Yarden, Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7, 505-16 (2006).
  4. Cohen-Dvashi, H. et al. Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression. EMBO Mol Med 7, 299-314 (2015).
  5. Ben-Chetrit, N. et al. Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Sci Signal 8, ra7 (2015).
  6. Katz, M. et al. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol 9, 961-9 (2007).
  7. Amit, I. et al. A module of negative feedback regulators defines growth factor signaling. Nat Genet 39, 503-12 (2007).
  8. Avraham, R. & Yarden, Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12, 104-17 (2011).
  9. Sas-Chen, A., Avraham, R. & Yarden, Y. A crossroad of microRNAs and immediate early genes (IEGs) encoding oncogenic transcription factors in breast cancer. J Mammary Gland Biol Neoplasia 17, 3-14 (2012).
  10. Avraham, R. et al. EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal 3, ra43 (2010).
  11. Kedmi, M. et al. EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Sci Signal 8, ra29 (2015).
  12. Enuka, Y. et al. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res 44, 1370-83 (2016).
  13. Carvalho, S. et al. An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors. Oncogene 35, 438-47 (2016).
  14. Gaborit, N. et al. Examination of HER3 targeting in cancer using monoclonal antibodies. Proc Natl Acad Sci U S A 112, 839-44 (2015).
  15. Lindzen, M. et al. A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene 31, 3505-15 (2012).
  16. Mahlknecht, G. et al. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci U S A 110, 8170-5 (2013).
  17. Klapper, L.N. et al. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14, 2099-109 (1997).
  18. Lindzen, M., Lavi, S., Leitner, O. & Yarden, Y. Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proc Natl Acad Sci U S A 107, 12559-63 (2010).
  19. Maron, R. et al. Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci U S A 110, 15389-94 (2013).
  20. Ferraro, D.A. et al. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci U S A 110, 1815-20 (2013).
  21. Mancini, M. et al. Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer. Sci Signal 8, ra53 (2015).
  22. Emde, A. et al. Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth. Oncogene 30, 1631-42 (2011).
  23. Ben-Kasus, T., Schechter, B., Lavi, S., Yarden, Y. & Sela, M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A 106, 3294-9 (2009).
  24. Carvalho, S., Levi-Schaffer, F., Sela, M. & Yarden, Y. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol 173, 1407-24 (2016).